A Randomised Controlled Trial of Early Vitrectomy and Intravitreal Antibiotics for Post-operative Exogenous Endophthalmitis (EVIAN study): study protocol for a feasibility trial

Mahiul Muhammed Khan Muqit, Carlos Pavesio, Hayley Boston, Keerththika Sriharan, Yanzhong Wang, Elena Pizzo, Stephen Cobb, Christopher Spink, James Bainbridge
{"title":"A Randomised Controlled Trial of Early Vitrectomy and Intravitreal Antibiotics for Post-operative Exogenous Endophthalmitis (EVIAN study): study protocol for a feasibility trial","authors":"Mahiul Muhammed Khan Muqit, Carlos Pavesio, Hayley Boston, Keerththika Sriharan, Yanzhong Wang, Elena Pizzo, Stephen Cobb, Christopher Spink, James Bainbridge","doi":"10.3310/nihropenres.13469.1","DOIUrl":null,"url":null,"abstract":"<ns3:p>Postoperative bacterial endophthalmitis is an infection of the eye's internal tissues resulting from an intraocular procedure. The condition is uncommon but can cause severe and irreversible impairment of sight. Standard management involves administration of antibiotics with or without subsequent removal of the infected vitreous gel by vitrectomy surgery. Surgical intervention is typically reserved for infections that persist despite a period of medical management alone. We aim to determine whether outcomes can be improved by performing surgery without delay. To explore the feasibility of a definitive randomised controlled trial and to determine the number of participants required, we will conduct a multicentre feasibility trial. This trial will include 40 affected individuals, allocated randomly to either standard of care, being intravitreal antibiotic administration alone, or to early vitrectomy surgery in addition to antibiotic administration. We will determine the feasibility and size of a definitive trial by evaluating the participants and the outcomes for their sight. Research Ethics Committee approval (REC 20/WM/0264). Here we describe the trial protocol. <ns3:bold>Trial registration number:</ns3:bold>ClinicalTrials.gov NCT04522661</ns3:p>","PeriodicalId":74312,"journal":{"name":"NIHR open research","volume":"49 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NIHR open research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3310/nihropenres.13469.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Postoperative bacterial endophthalmitis is an infection of the eye's internal tissues resulting from an intraocular procedure. The condition is uncommon but can cause severe and irreversible impairment of sight. Standard management involves administration of antibiotics with or without subsequent removal of the infected vitreous gel by vitrectomy surgery. Surgical intervention is typically reserved for infections that persist despite a period of medical management alone. We aim to determine whether outcomes can be improved by performing surgery without delay. To explore the feasibility of a definitive randomised controlled trial and to determine the number of participants required, we will conduct a multicentre feasibility trial. This trial will include 40 affected individuals, allocated randomly to either standard of care, being intravitreal antibiotic administration alone, or to early vitrectomy surgery in addition to antibiotic administration. We will determine the feasibility and size of a definitive trial by evaluating the participants and the outcomes for their sight. Research Ethics Committee approval (REC 20/WM/0264). Here we describe the trial protocol. Trial registration number:ClinicalTrials.gov NCT04522661
早期玻璃体切除术和玻璃体内抗生素治疗术后外源性眼内炎的随机对照试验(EVIAN研究):可行性试验的研究方案
术后细菌性眼内炎是眼内手术引起的眼睛内部组织感染。这种情况并不常见,但会导致严重的、不可逆转的视力损害。标准的治疗包括使用抗生素,并或不随后通过玻璃体切割手术去除受感染的玻璃体凝胶。手术干预通常保留在感染持续,尽管一段时间的医疗管理单独。我们的目的是确定是否可以通过立即进行手术来改善预后。为了探索一项明确的随机对照试验的可行性,并确定所需的参与者人数,我们将进行一项多中心可行性试验。该试验将包括40名受影响的个体,随机分配到标准护理组,单独给予玻璃体内抗生素,或早期玻璃体切除手术加上抗生素。我们将通过评估参与者和他们视力的结果来确定最终试验的可行性和规模。研究伦理委员会批准(REC 20/WM/0264)。这里我们描述试验方案。试验注册号:ClinicalTrials.gov NCT04522661
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信